Influence of Solute Carrier Family 22 Member 1 (SLC22A1) Gene Polymorphism on Metformin Pharmacokinetics and HbA1c Levels: A Systematic Review.

IF 2.4 Q3 ENDOCRINOLOGY & METABOLISM

Current diabetes reviews Pub Date : 2024-01-01 DOI:10.2174/1573399820666230807145202

A D Pradana, E Kristin, D A A Nugrahaningsih, A K Nugroho, R T Pinzon

{"title":"Influence of Solute Carrier Family 22 Member 1 (SLC22A1) Gene Polymorphism on Metformin Pharmacokinetics and HbA1c Levels: A Systematic Review.","authors":"A D Pradana, E Kristin, D A A Nugrahaningsih, A K Nugroho, R T Pinzon","doi":"10.2174/1573399820666230807145202","DOIUrl":null,"url":null,"abstract":"Background: Solute Carrier Family 22 Member 1 (SLC22A1, also known as OCT1) protein has a vital role in the metabolism of metformin, a first-line anti-diabetes medication. Genetic poly-morphism in SLC22A1 influences individual response to metformin.Objective: This review aims to compile the current knowledge about the effects of SLC22A1 genetic polymorphism on metformin pharmacokinetics and HbA1c levels.Methods: We followed the PRISMA 2020 standards to conduct a systematic review. We searched the publications for all appropriate evidence on the effects of SLC22A1 genetic polymorphism on metformin pharmacokinetics and HbA1c from January 2002 to December 2022.Results: Initial database searches identified 7,171 relevant studies. We reviewed 155 titles and abstracts after deleting duplicates. After applying inclusion and exclusion criteria, 23 studies remained.Conclusion: Three studies found that rs12208357, rs34059508, and G465R had a considerable impact (p < 0.05) on metformin pharmacokinetics, resulting in increased metformin plasma (Cmax), a higher active amount of drug in the blood (AUC), and lower volume of distribution (Vd) (p<0.05). SLC22A1 polymorphisms with effects on HbA1c include rs628031 (four of seven studies), rs622342 (four of six studies), rs594709 (one study), rs2297374, and rs1867351 (one of two studies), rs34130495 (one study), and rs11212617 (one study) (p < 0.05).","PeriodicalId":10825,"journal":{"name":"Current diabetes reviews","volume":" ","pages":"e070823219470"},"PeriodicalIF":2.4000,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Current diabetes reviews","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.2174/1573399820666230807145202","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"ENDOCRINOLOGY & METABOLISM","Score":null,"Total":0}

引用次数: 0

Abstract

Background: Solute Carrier Family 22 Member 1 (SLC22A1, also known as OCT1) protein has a vital role in the metabolism of metformin, a first-line anti-diabetes medication. Genetic poly-morphism in SLC22A1 influences individual response to metformin.

Objective: This review aims to compile the current knowledge about the effects of SLC22A1 genetic polymorphism on metformin pharmacokinetics and HbA1c levels.

Methods: We followed the PRISMA 2020 standards to conduct a systematic review. We searched the publications for all appropriate evidence on the effects of SLC22A1 genetic polymorphism on metformin pharmacokinetics and HbA1c from January 2002 to December 2022.

Results: Initial database searches identified 7,171 relevant studies. We reviewed 155 titles and abstracts after deleting duplicates. After applying inclusion and exclusion criteria, 23 studies remained.

Conclusion: Three studies found that rs12208357, rs34059508, and G465R had a considerable impact (p < 0.05) on metformin pharmacokinetics, resulting in increased metformin plasma (Cmax), a higher active amount of drug in the blood (AUC), and lower volume of distribution (Vd) (p<0.05). SLC22A1 polymorphisms with effects on HbA1c include rs628031 (four of seven studies), rs622342 (four of six studies), rs594709 (one study), rs2297374, and rs1867351 (one of two studies), rs34130495 (one study), and rs11212617 (one study) (p < 0.05).

查看原文本刊更多论文

溶质载体家族 22 成员 1 (SLC22A1) 基因多态性对二甲双胍药代动力学和 HbA1c 水平的影响：系统综述。

背景：溶质运载家族 22 成员 1（SLC22A1，又称 OCT1）蛋白在二甲双胍的代谢过程中起着至关重要的作用，二甲双胍是一种一线抗糖尿病药物。SLC22A1 的遗传多态性会影响个体对二甲双胍的反应：本综述旨在梳理目前有关 SLC22A1 基因多态性对二甲双胍药代动力学和 HbA1c 水平影响的知识：我们按照 PRISMA 2020 标准进行了系统性综述。我们检索了 2002 年 1 月至 2022 年 12 月期间有关 SLC22A1 基因多态性对二甲双胍药代动力学和 HbA1c 影响的所有相关证据：最初的数据库检索发现了 7,171 项相关研究。删除重复内容后，我们审阅了 155 篇标题和摘要。在应用纳入和排除标准后，剩下 23 项研究：三项研究发现，rs12208357、rs34059508 和 G465R 对二甲双胍药代动力学有相当大的影响（p< 0.05），导致二甲双胍血浆（Cmax）升高，血液中药物活性量（AUC）升高，分布容积（Vd）降低（p<0.05）。对 HbA1c 有影响的 SLC22A1 多态性包括 rs628031（7 项研究中的 4 项）、rs622342（6 项研究中的 4 项）、rs594709（1 项研究）、rs2297374 和 rs1867351（2 项研究中的 1 项）、rs34130495（1 项研究）和 rs11212617（1 项研究）（p<0.05）。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Current diabetes reviews ENDOCRINOLOGY & METABOLISM-

CiteScore

6.30

自引率

0.00%

发文量

158

期刊介绍： Current Diabetes Reviews publishes frontier reviews on all the latest advances on diabetes and its related areas e.g. pharmacology, pathogenesis, complications, epidemiology, clinical care, and therapy. The journal"s aim is to publish the highest quality review articles dedicated to clinical research in the field. The journal is essential reading for all researchers and clinicians who are involved in the field of diabetes.